LIVN logo

LIVANOVA PLC

LIVNNASDAQ
πŸ† #1333 by market capEarnings Nov 4 Β· PreUS Equity
$80.61β–² $0.27 (+0.34%)
Pre-market Β· at close
πŸ””
Track LIVN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.3%
7dβ–Ό 0.9%
14dβ–² 2.7%
30dβ–² 4.7%
ytdβ–² 31.0%
1yβ–² 51.3%
🏦Market Cap
$4.44B
Small Cap
πŸ“ˆRevenue Growth (YoY)
12.4%
Healthy
πŸ“ŠGross Margin
68.1%
High
πŸ’΅FCF Margin
10.1%
Healthy
βš–οΈP/S Ratio
3.0x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$80.37 – $81.89
52-Week Range
$48.82 – $85.76
Volume (shares)
36,908
Avg Volume (shares)
β€”
Shares Outstanding
55.1M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$1.39B
Last Q Revenue
$391M
P/E Ratio
23.6
P/S Ratio
3.0x
EPS (TTM)
$3.38
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.4%
LIVN logo

LIVANOVA PLC

LIVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.4Bβ–² +10.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.7%β–Ό βˆ’2.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$199Mβ–² +54.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$173Mβ–² +27.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
54.5Mβ–Ό βˆ’0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$162Mβ–² +$410M YoY
StockOtter Β· stockotter.space

About LIVANOVA PLC

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
16 analysts
Strong Buy6
Buy7
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.